BSE Live
Apr 09, 16:01Prev. Close
669.25
Open Price
680.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 09, 15:58Prev. Close
671.05
Open Price
675.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
725.80 (211)
| Key Financial Ratios of Albert David (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 30.14 | 132.15 | 63.39 | 61.78 | 38.80 | |
| Diluted EPS (Rs.) | 30.14 | 132.15 | 63.39 | 61.78 | 38.80 | |
| Cash EPS (Rs.) | 42.35 | 144.11 | 78.36 | 77.21 | 53.22 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 687.70 | 671.05 | 545.93 | 489.68 | 428.20 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 687.70 | 671.05 | 545.93 | 489.68 | 428.20 | |
| Dividend / Share(Rs.) | 5.00 | 11.50 | 9.00 | 9.00 | 6.00 | |
| Revenue from Operations/Share (Rs.) | 605.85 | 635.10 | 598.48 | 549.33 | 433.57 | |
| PBDIT/Share (Rs.) | 57.13 | 182.98 | 104.67 | 99.24 | 63.65 | |
| PBIT/Share (Rs.) | 44.92 | 171.02 | 89.70 | 83.81 | 49.23 | |
| PBT/Share (Rs.) | 44.20 | 170.46 | 88.90 | 82.87 | 48.09 | |
| Net Profit/Share (Rs.) | 30.14 | 132.15 | 63.38 | 61.78 | 38.80 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 9.43 | 28.81 | 17.49 | 18.06 | 14.68 | |
| PBIT Margin (%) | 7.41 | 26.92 | 14.98 | 15.25 | 11.35 | |
| PBT Margin (%) | 7.29 | 26.84 | 14.85 | 15.08 | 11.09 | |
| Net Profit Margin (%) | 4.97 | 20.80 | 10.59 | 11.24 | 8.94 | |
| Return on Networth / Equity (%) | 4.38 | 19.69 | 11.61 | 12.61 | 9.06 | |
| Return on Capital Employed (%) | 6.29 | 24.46 | 15.77 | 16.27 | 10.77 | |
| Return on Assets (%) | 3.36 | 15.14 | 8.54 | 8.75 | 6.48 | |
| Total Debt/Equity (X) | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 | |
| Asset Turnover Ratio (%) | 0.69 | 0.79 | 0.83 | 0.84 | 0.75 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.40 | 3.75 | 3.07 | 2.33 | 2.77 | |
| Quick Ratio (X) | 2.79 | 3.31 | 2.55 | 1.97 | 2.33 | |
| Inventory Turnover Ratio (X) | 6.43 | 1.36 | 1.41 | 1.37 | 0.94 | |
| Dividend Payout Ratio (NP) (%) | 38.15 | 6.81 | 14.19 | 9.71 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 27.15 | 6.24 | 11.48 | 7.77 | 0.00 | |
| Earnings Retention Ratio (%) | 61.85 | 93.19 | 85.81 | 90.29 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 72.85 | 93.76 | 88.52 | 92.23 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 471.38 | 584.89 | 270.90 | 288.62 | 180.08 | |
| EV/Net Operating Revenue (X) | 1.36 | 1.61 | 0.79 | 0.92 | 0.73 | |
| EV/EBITDA (X) | 14.46 | 5.60 | 4.53 | 5.10 | 4.96 | |
| MarketCap/Net Operating Revenue (X) | 1.34 | 1.69 | 0.86 | 0.97 | 0.87 | |
| Retention Ratios (%) | 61.84 | 93.18 | 85.80 | 90.28 | 0.00 | |
| Price/BV (X) | 1.18 | 1.60 | 0.94 | 1.09 | 0.88 | |
| Price/Net Operating Revenue | 1.34 | 1.69 | 0.86 | 0.97 | 0.87 | |
| Earnings Yield | 0.04 | 0.12 | 0.12 | 0.12 | 0.10 |
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth